Halozyme Therapeutics (HALO) Tops Q4 EPS by 2c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $128.95 -1.5%
EPS Growth %: +32.6%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
LTBR, AES, SYRS, More
EPS Growth %: +32.6%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of $0.82, $0.02 better than the analyst estimate of $0.80. Revenue for the quarter came in at $230 million versus the consensus estimate of $232 million.
GUIDANCE:
Halozyme Therapeutics sees FY2024 EPS of $3.55-$3.90, versus the consensus of $3.64. Halozyme Therapeutics sees FY2024 revenue of $915-985 million, versus the consensus of $961.1 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Calix, Inc. (CALX) Tops Q3 EPS by 3c; offers guidance
- Voyager Technologies, Inc. (VOYG) Misses Q3 EPS by 55c; Offer Guidance
- Janus Living, Inc. (JAN) Reports Q3 Loss of $0.02 ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
